S&P 500   4,604.39 (+0.00%)
DOW   36,331.78 (+0.23%)
QQQ   393.09 (+0.23%)
AAPL   191.81 (-1.99%)
MSFT   368.63 (-1.50%)
META   321.03 (-3.52%)
GOOGL   132.33 (-1.97%)
AMZN   144.88 (-1.72%)
TSLA   239.89 (-1.62%)
NVDA   460.18 (-3.13%)
NIO   7.47 (+1.22%)
BABA   71.52 (-0.86%)
AMD   133.34 (+3.43%)
T   16.67 (-1.48%)
F   11.09 (+0.73%)
MU   77.70 (+3.66%)
CGC   0.81 (+0.73%)
GE   120.29 (-0.25%)
DIS   92.74 (-0.09%)
AMC   6.85 (-1.15%)
PFE   28.57 (-0.73%)
PYPL   59.31 (+0.63%)
XOM   99.25 (-0.30%)
S&P 500   4,604.39 (+0.00%)
DOW   36,331.78 (+0.23%)
QQQ   393.09 (+0.23%)
AAPL   191.81 (-1.99%)
MSFT   368.63 (-1.50%)
META   321.03 (-3.52%)
GOOGL   132.33 (-1.97%)
AMZN   144.88 (-1.72%)
TSLA   239.89 (-1.62%)
NVDA   460.18 (-3.13%)
NIO   7.47 (+1.22%)
BABA   71.52 (-0.86%)
AMD   133.34 (+3.43%)
T   16.67 (-1.48%)
F   11.09 (+0.73%)
MU   77.70 (+3.66%)
CGC   0.81 (+0.73%)
GE   120.29 (-0.25%)
DIS   92.74 (-0.09%)
AMC   6.85 (-1.15%)
PFE   28.57 (-0.73%)
PYPL   59.31 (+0.63%)
XOM   99.25 (-0.30%)
S&P 500   4,604.39 (+0.00%)
DOW   36,331.78 (+0.23%)
QQQ   393.09 (+0.23%)
AAPL   191.81 (-1.99%)
MSFT   368.63 (-1.50%)
META   321.03 (-3.52%)
GOOGL   132.33 (-1.97%)
AMZN   144.88 (-1.72%)
TSLA   239.89 (-1.62%)
NVDA   460.18 (-3.13%)
NIO   7.47 (+1.22%)
BABA   71.52 (-0.86%)
AMD   133.34 (+3.43%)
T   16.67 (-1.48%)
F   11.09 (+0.73%)
MU   77.70 (+3.66%)
CGC   0.81 (+0.73%)
GE   120.29 (-0.25%)
DIS   92.74 (-0.09%)
AMC   6.85 (-1.15%)
PFE   28.57 (-0.73%)
PYPL   59.31 (+0.63%)
XOM   99.25 (-0.30%)
S&P 500   4,604.39 (+0.00%)
DOW   36,331.78 (+0.23%)
QQQ   393.09 (+0.23%)
AAPL   191.81 (-1.99%)
MSFT   368.63 (-1.50%)
META   321.03 (-3.52%)
GOOGL   132.33 (-1.97%)
AMZN   144.88 (-1.72%)
TSLA   239.89 (-1.62%)
NVDA   460.18 (-3.13%)
NIO   7.47 (+1.22%)
BABA   71.52 (-0.86%)
AMD   133.34 (+3.43%)
T   16.67 (-1.48%)
F   11.09 (+0.73%)
MU   77.70 (+3.66%)
CGC   0.81 (+0.73%)
GE   120.29 (-0.25%)
DIS   92.74 (-0.09%)
AMC   6.85 (-1.15%)
PFE   28.57 (-0.73%)
PYPL   59.31 (+0.63%)
XOM   99.25 (-0.30%)

Baxter International (BAX) Stock Price, News & Analysis

$36.46
+0.31 (+0.86%)
(As of 11:27 AM ET)
Compare
Today's Range
$36.08
▼
$36.49
50-Day Range
$31.71
▼
$37.36
52-Week Range
$31.01
▼
$53.80
Volume
952,910 shs
Average Volume
5.41 million shs
Market Capitalization
$18.50 billion
P/E Ratio
7.15
Dividend Yield
3.18%
Price Target
$46.83
Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability

Baxter International MarketRank™ Stock Analysis

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
29.6% Upside
$46.83 Price Target
Short Interest
Healthy
2.04% of Shares Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-1.95
Upright™ Environmental Score
News Sentiment
0.07mentions of Baxter International in the last 14 days
Based on 11 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
14.62%
From $2.60 to $2.98 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.93 out of 5 stars

Medical Sector

32nd out of 942 stocks

Surgical & Medical Instruments Industry

9th out of 94 stocks

See Top Rated MarketRank™ Stocks Here

BAX stock logo

About Baxter International Stock (NYSE:BAX)

Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; premixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention; and continuous renal replacement therapies and other organ support therapies focused in the intensive care unit. It also provides connected care solutions, including devices, software, communications, and integration technologies; integrated patient monitoring and diagnostic technologies to help diagnose, treat, and manage a various illness and diseases, including respiratory therapy, cardiology, vision screening, and physical assessment; surgical video technologies, tables, lights, pendants, precision positioning devices and other accessories. In addition, the company offers contracted services to various pharmaceutical and biopharmaceutical companies. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules; and a collaborative research agreement with Miromatrix Medical Inc. to develop treatments for patients with acute liver failure. Baxter International Inc. was incorporated in 1931 and is based in Deerfield, Illinois.

BAX Stock Price History

BAX Stock News Headlines

December 11, 2023 | finance.yahoo.com
Baxter Publishes Task Force on Climate-Related Financial Disclosures (TCFD) Report and Is Named to Dow Jones Sustainability Index North America
December 10, 2023 | americanbankingnews.com
Baxter International Inc. (NYSE:BAX) Given Consensus Rating of "Hold" by Brokerages
December 11, 2023 | DTI Trader (Ad)
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
December 8, 2023 | yahoo.com
Holly Waddington on Dressing the Fantastical World of ‘Poor Things’
December 8, 2023 | msn.com
Baxter makes six changes for Exeter trip to Toulon
December 7, 2023 | americanbankingnews.com
Analyzing Coloplast A/S (OTCMKTS:CLPBF) and Baxter International (NYSE:BAX)
December 6, 2023 | americanbankingnews.com
Baxter International (NYSE:BAX) Downgraded to Hold at StockNews.com
December 6, 2023 | markets.businessinsider.com
Baxter International Spin-Off Analysis: Hold Rating with Adjusted Price Objective
December 11, 2023 | Wealthpress (Ad)
Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
December 5, 2023 | americanbankingnews.com
Morgan Stanley Cuts Baxter International (NYSE:BAX) Price Target to $39.00
December 4, 2023 | markets.businessinsider.com
Morgan Stanley Maintains Equal-Weight Rating for Baxter Intl: Here's What You Need To Know
December 4, 2023 | finance.yahoo.com
Spectral Medical Provides November Tigris Trial Update
November 29, 2023 | msn.com
Sin-bins in football: Exeter Chiefs rugby union boss Rob Baxter urges caution from game's lawmakers
November 29, 2023 | finance.yahoo.com
Michener-Baxter Award for Excellence in Canadian Journalism Open for Nominations
November 29, 2023 | msn.com
Exeter boss Rob Baxter has issued a sin-bin warning to football
November 29, 2023 | theguardian.com
Exeter’s Rob Baxter warns football to be careful what it wishes for with sin-bins
November 29, 2023 | msn.com
Rob Baxter: Football must learn from rugby's mistakes of opening Pandora's Box of technology
November 28, 2023 | cbsnews.com
Day of Giving: A big donation to the Red Cross from the Baxter International Foundation
November 28, 2023 | finance.yahoo.com
The Baxter International Foundation and UNICEF Partner to Expand Access to Safe Water and Sanitation in Egypt
November 26, 2023 | msn.com
Best round of the day helps England’s James Baxter bag Sharjah Men’s Open
November 22, 2023 | benzinga.com
Hemostats Market worth $3.7 billion by 2028
November 22, 2023 | msn.com
Eyes of Texas are now upon Edgewater product CJ Baxter
November 21, 2023 | msn.com
Is truth better than fiction? Thomas Rongen’s story loses something in ‘Next Goal Wins’
November 20, 2023 | au.lifestyle.yahoo.com
Exeter's Gloucester win reminds boss Rob Baxter of title-chasers
November 20, 2023 | finance.yahoo.com
Estimating The Fair Value Of Baxter International Inc. (NYSE:BAX)
November 16, 2023 | msn.com
Baxter recalls Novum IQ Syringe Pumps over software error
November 16, 2023 | uk.news.yahoo.com
Crusaders boss Stephen Baxter confident Irish League managers could make an impact across the water
See More Headlines
Receive BAX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Baxter International and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 10/2 Dividend
8/31/2023
Dividend Payable
10/02/2023
Last Earnings
11/02/2023
Ex-Dividend for 1/2 Dividend
11/30/2023
Today
12/11/2023
Fiscal Year End
12/31/2023
Dividend Payable
1/02/2024
Next Earnings (Estimated)
2/08/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Sector
Medical
Current Symbol
NYSE:BAX
CUSIP
07181310
CIK
10456
Web
www.baxter.com
Phone
(224) 948-2000
Fax
224-948-1813
Employees
60,000
Year Founded
1931

Price Target and Rating

Average Stock Price Target
$46.83
High Stock Price Target
$56.00
Low Stock Price Target
$36.00
Potential Upside/Downside
+29.6%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
12 Analysts

Profitability

EPS (Most Recent Fiscal Year)
$5.10
Trailing P/E Ratio
7.09
Forward P/E Ratio
13.90
P/E Growth
2.69
Net Income
$-2,433,000,000.00
Net Margins
17.34%
Pretax Margin
0.63%
Return on Equity
21.38%
Return on Assets
4.76%

Debt

Debt-to-Equity Ratio
1.72
Current Ratio
1.94
Quick Ratio
1.48

Sales & Book Value

Annual Sales
$15.11 billion
Price / Sales
1.21
Cash Flow
$12.42 per share
Price / Cash Flow
2.91
Book Value
$11.69 per share
Price / Book
3.09

Miscellaneous

Outstanding Shares
507,320,000
Free Float
506,259,000
Market Cap
$18.34 billion
Optionable
Optionable
Beta
0.61

Social Links

Metaverse Stocks And Why You Can't Ignore Them Cover
Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Mr. Jose E. Almeida (Age 61)
    Chairman of the Board, President & CEO
    Comp: $2.1M
  • Mr. David S. Rosenbloom (Age 63)
    Executive VP & General Counsel
    Comp: $776.51k
  • Mr. Joel T. Grade (Age 52)
    Executive VP & CFO
  • Mr. Talvis P. Love (Age 55)
    Senior VP & Chief Information Officer
  • Ms. Tobi Karchmer M.D.
    M.S., Senior VP and Chief Medical & Scientific Officer
  • Ms. Clare Trachtman
    Vice President of Investor Relations
  • Ms. Stacey Eisen
    Senior Vice President of Global Communications
  • Ms. Jeanne K. Mason Ph.D.Ms. Jeanne K. Mason Ph.D. (Age 67)
    ?Executive VP & Chief Human Resources Officer
    Comp: $1.99M
  • Mr. James W. Borzi (Age 60)
    Executive VP & Chief Supply Chain Officer
  • Ms. Heather Knight
    Executive VP & Group President of Medical Products and Therapies

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

Should I Buy Baxter International Stock? BAX Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Baxter International was last updated on Tuesday, November 28, 2023 at 10:38 PM.

Pros

Here are some ways that investors could benefit from investing in Baxter International Inc.:

  • Baxter International Inc. has reported a 3% year-on-year rise in quarterly revenue, indicating growth in the company's financial performance.
  • The demand for Baxter's medical devices has been strong, driven by a recovery in surgical procedure volumes after the pandemic. This suggests a positive outlook for the company's products.
  • Baxter International Inc. offers a diverse portfolio of healthcare products, including peritoneal dialysis and hemodialysis therapies, intravenous therapies, and parenteral nutrition therapies. This diversification can provide stability and potential growth opportunities for investors.
  • The company has a global presence, selling its products in approximately 100 countries. This international reach allows Baxter to tap into various markets and potentially expand its customer base.
  • Baxter International Inc. provides connected care solutions, including devices, software, and integration technologies. This focus on connected care can position the company to benefit from the growing trend of digital healthcare solutions.

Cons

Investors should be bearish about investing in Baxter International Inc. for these reasons:

  • While Baxter has reported growth in quarterly revenue, it is important to consider the sustainability of this growth and potential challenges the company may face in the future.
  • The healthcare industry is subject to regulatory changes and evolving market dynamics. Investors should closely monitor any potential regulatory risks or shifts in market conditions that could impact Baxter's business.
  • Competition within the healthcare equipment industry is intense, with numerous companies vying for market share. Baxter International Inc. must continue to innovate and differentiate its products to stay competitive.
  • Investors should consider the potential impact of economic downturns or disruptions on Baxter's business. Economic uncertainties can affect healthcare spending and demand for the company's products.
  • Stock price fluctuations are inherent in the stock market. Investors should carefully analyze the current stock price of Baxter International Inc. and consider factors such as valuation, market trends, and company performance before making investment decisions.














BAX Stock Analysis - Frequently Asked Questions

Should I buy or sell Baxter International stock right now?

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Baxter International in the last twelve months. There are currently 8 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" BAX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BAX, but not buy additional shares or sell existing shares.
View BAX analyst ratings or view top-rated stocks.

What is Baxter International's stock price target for 2024?

12 brokerages have issued 1-year price objectives for Baxter International's stock. Their BAX share price targets range from $36.00 to $56.00. On average, they expect the company's stock price to reach $46.83 in the next year. This suggests a possible upside of 29.6% from the stock's current price.
View analysts price targets for BAX or view top-rated stocks among Wall Street analysts.

How have BAX shares performed in 2023?

Baxter International's stock was trading at $50.97 at the beginning of 2023. Since then, BAX stock has decreased by 29.1% and is now trading at $36.15.
View the best growth stocks for 2023 here.

Are investors shorting Baxter International?

Baxter International saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 10,340,000 shares, an increase of 13.6% from the October 31st total of 9,100,000 shares. Based on an average daily trading volume, of 5,040,000 shares, the short-interest ratio is presently 2.1 days.
View Baxter International's Short Interest.

When is Baxter International's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 8th 2024.
View our BAX earnings forecast.

How were Baxter International's earnings last quarter?

Baxter International Inc. (NYSE:BAX) issued its quarterly earnings results on Thursday, November, 2nd. The medical instruments supplier reported $0.68 earnings per share for the quarter, topping analysts' consensus estimates of $0.66 by $0.02. The medical instruments supplier earned $3.71 billion during the quarter, compared to analyst estimates of $3.69 billion. Baxter International had a net margin of 17.34% and a trailing twelve-month return on equity of 21.38%.

How often does Baxter International pay dividends? What is the dividend yield for Baxter International?

Baxter International declared a quarterly dividend on Tuesday, November 14th. Investors of record on Friday, December 1st will be given a dividend of $0.29 per share on Tuesday, January 2nd. This represents a $1.16 annualized dividend and a yield of 3.21%. The ex-dividend date is Thursday, November 30th.
Read our dividend analysis for BAX.

Is Baxter International a good dividend stock?

Baxter International (NYSE:BAX) pays an annual dividend of $1.16 per share and currently has a dividend yield of 3.18%. The company has been increasing its dividend for 7 consecutive years, indicating the company has a new, but growing committment to grow its dividend. The dividend payout ratio is 22.75%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, BAX will have a dividend payout ratio of 38.93% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for BAX.

What ETFs hold Baxter International's stock?

ETFs with the largest weight of Baxter International (NYSE:BAX) stock in their portfolio include Simplify Health Care ETF (PINK), BTD Capital Fund (DIP), First Trust Indxx Medical Devices ETF (MDEV), iShares U.S. Medical Devices ETF (IHI), BlackRock Large Cap Value ETF (BLCV), Invesco Zacks Mid-Cap ETF (CZA), Invesco S&P 500 Equal Weight Health Care ETF (RYH) and SPDR S&P Health Care Equipment ETF (XHE).

What guidance has Baxter International issued on next quarter's earnings?

Baxter International updated its fourth quarter earnings guidance on Thursday, November, 2nd. The company provided earnings per share guidance of $0.85-$0.88 for the period, compared to the consensus earnings per share estimate of $0.85. The company issued revenue guidance of $3.93-$3.96 billion, compared to the consensus revenue estimate of $3.83 billion.

What is José (Joe) Almeida's approval rating as Baxter International's CEO?

506 employees have rated Baxter International Chief Executive Officer José (Joe) Almeida on Glassdoor.com. José (Joe) Almeida has an approval rating of 85% among the company's employees.

What other stocks do shareholders of Baxter International own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Baxter International investors own include CA (CA), Johnson & Johnson (JNJ), Pfizer (PFE), Cisco Systems (CSCO), Intel (INTC), Abbott Laboratories (ABT), Procter & Gamble (PG), AT&T (T) and Verizon Communications (VZ).

Who are Baxter International's major shareholders?

Baxter International's stock is owned by a variety of retail and institutional investors. Top institutional investors include Ameriprise Financial Inc. (2.14%), Bank of New York Mellon Corp (1.28%), Pzena Investment Management LLC (1.13%), Carmignac Gestion (0.96%), California Public Employees Retirement System (0.62%) and Shapiro Capital Management LLC (0.60%). Insiders that own company stock include Albert P L Stroucken, Andrew Frye, Brian Stevens, Jacqueline Kunzler and Jeanne K Mason.
View institutional ownership trends.

How do I buy shares of Baxter International?

Shares of BAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

Does Baxter International have any subsidiaries?
The following companies are subsidiares of Baxter International: ApaTech Limited, Baxter (China) Investment Co. Ltd, Baxter (Hellas) EPE, Baxter (India) Private Limited, Baxter AO, Baxter Belgium SPRL, Baxter Company Ltd, Baxter Corporation (Canada), Baxter Corporation Englewood, Baxter Deutschland GmbH, Baxter Distribution Center Europe SA, Baxter Healthcare (Guangzhou) Company Ltd, Baxter Healthcare (Shanghai) Company Ltd., Baxter Healthcare (Suzhou) Company Ltd, Baxter Healthcare (Thailand) Company Limited, Baxter Healthcare (Tianjin) Co. Ltd., Baxter Healthcare Corporation, Baxter Healthcare Limited, Baxter Healthcare Limited (Hong Kong China), Baxter Healthcare Limited (Taiwan), Baxter Healthcare Pty Ltd, Baxter Healthcare SA, Baxter Healthcare SA (Singapore Woodlands Branch), Baxter Healthcare Trading (Shanghai) Co. Ltd., Baxter Holding B.V., Baxter Hospitalar Ltda., Baxter Incorporated, Baxter Innovations & Business Solutions Private Limited (India), Baxter Limited, Baxter Manufacturing (Thailand) Co. Ltd., Baxter Medical AB, Baxter Oncology GmbH, Baxter Pharmaceutical Solutions LLC, Baxter Pharmaceuticals (Asia) Pte Ltd., Baxter Pharmaceuticals India Pvt Ltd., Baxter Polska Sp. z o.o., Baxter Productos Medicos Ltda., Baxter R and D Europe SPRL, Baxter S.A. de C.V., Baxter S.A.S., Baxter S.L., Baxter S.p.A., Baxter SA, Baxter Sales and Distribution LLC, Baxter Services Europe SA, Baxter Shared Services & Competencies Limited, Baxter de Guatemala Sociedad Anonima, Bieffe Medital S.p.A., Cheetah Medical, Cheetah Medical (Israel) Ltd., Cheetah Medical (UK) Limited, Cheetah Medical Inc., Gambro AB, Gambro Dasco S.p.A., Gambro Dialysatoren GmbH, Gambro Industries SAS, Gambro Lundia AB, Gambro Renal Products Inc., Laboratorios Baxter S.A., RTS Colombia SAS, Synovis Life Technologies Inc., and Synovis Micro Companies Alliance Inc..
Read More
This page (NYSE:BAX) was last updated on 12/11/2023 by MarketBeat.com Staff

My Account -